Page 1

Axonics® Reports Third Quarter 2021 Financial Results Exhibit 99.1 - IRVINE , Calif - November 4 , 2021 Axonics , Inc. ( Nasdaq : AXNX ) , a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction , today reported financial results for the third quarter ended September 30 , 2021 . " We are pleased with this quarter's revenue result considering the significant impact the surge in Covid - 19 Delta variant cases had on elective procedure volumes in August and September , in addition to staffing shortages at hospitals and seasonality from summer vacations , ” said Raymond W. Cohen , chief executive officer of Axonics . “ Bulkamid® posted its highest revenue quarter to date and has proven to be more insulated from Covid - 19 impact due to physicians having the option to perform the procedure in their offices . ” Cohen continued , “ Over the last four months , we have had the pleasure of hosting 325 physicians at six regional seminars to introduce Bulkamid and provide proctored wet lab training . The programs also provided us with an opportunity to introduce our sacral neuromodulation system to physicians who are less familiar with Axonics and have them hear firsthand from their peers who have already experienced the difference of working with Axonics . The overwhelmingly positive feedback from physicians at these seminars reinforces our confidence that the SNM market will grow considerably once Covid - 19 subsides and that Axonics ' best - in - class incontinence solutions will drive durable growth for years to come . " Third Quarter 2021 Financial Results • Net revenue was $ 46.9 million in third quarter 2021 , an increase of 33 % compared to $ 35.2 million in the prior year period . ° Sacral neuromodulation ( SNM ) revenue was $ 40.1 million , of which $ 39.1 million was generated in the U.S. and the remainder in select international markets . . о Bulkamid revenue was $ 6.8 million , of which $ 3.9 million was generated in the U.S. and the remainder in international markets . Gross margin was 66.5 % in third quarter 2021 compared to 61.9 % in the prior year period . • Operating expenses were $ 47.7 million in third quarter 2021 compared to $ 30.6 million in the prior year period . • Net loss was $ 17.3 million in third quarter 2021 compared to a net loss of $ 9.2 million in the prior year period . • As of September 30 , 2021 , cash and cash equivalents were $ 228.8 million . 2021 Revenue Guidance Axonics continues to closely monitor the impact that the Covid - 19 pandemic has had , and continues to have , on elective procedure volumes . Based on third quarter results as well as continuing disruptions from Covid - 19 and hospital staffing shortages potentially slowing the recovery in elective procedure volumes , Axonics is updating its 2021 guidance as follows : Fiscal year 2021 total company revenue of $ 177.0 million , an increase of 59 % compared to fiscal year 2020 . о 4Q21 total company revenue of $ 49.8 million , an increase of 43 % compared to 4Q20 .